title: Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
abstract: BACKGROUND
  Angiogenesis plays an important role in tumor progression. The vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis. In the present study we evaluated single nucleotide polymorphisms (SNPs) -2578C > A, -1154G > A, and +936C > T in the VEGF gene, and their prognostic value for patients operated on for colorectal cancer (CRC).
  
  
  METHODS
  VEGF polymorphisms have been analyzed in 177 patients who had undergone surgical resection at Hospital Clínico San Carlos. The analysis of these polymorphisms was performed with specific probes for each nucleotide in a multiplex reaction using real-time PCR.
  
  
  RESULTS
  We only found a statistically significant relationship for one of these three polymorphisms, +936C > T, with gender and tumor location; 10.7% of patients heterozygotes for this SNP had tumors located in proximal colon, 35.2% in distal segment and 54.1% in rectum (p = 0.03). Patients with the +936T/T genotype had 100% overall survival (OS).
  
  
  CONCLUSIONS
  Patients with a +936T/T genotype showed increased survival, therefore the +936C > T SNP could be a useful marker in the follow-up and clinical management of patients with colorectal cancer.
authors.affiliation: Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Vidaurreta
authors.forename: R
authors.initials: R
authors.lastname: Sánchez-Muñoz
authors.forename: S
authors.initials: S
authors.lastname: Veganzones
authors.forename: S
authors.initials: S
authors.lastname: Rafael
authors.forename: M
authors.initials: M
authors.lastname: Gutiérrez
authors.forename: V
authors.initials: V
authors.lastname: de-la-Orden
authors.forename: C
authors.initials: C
authors.lastname: Fernández
authors.forename: M
authors.initials: M
authors.lastname: Arroyo
authors.forename: F J
authors.initials: FJ
authors.lastname: Cerdán
authors.forename: Ma Luisa
authors.initials: ML
authors.lastname: Maestro de las Casas
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003082:Colectomy; D003110:Colonic Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics* / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D012004:Rectal Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics* / Q000502:physiology
chemical_list: D000964:Antimetabolites, Antineoplastic; D009363:Neoplasm Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D002955:Leucovorin; D005472:Fluorouracil